Sign in

CIK 0001933414

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Mineralys Therapeutics, Inc.

Sign in to watch
Ticker
MLYS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
841966887
Phone
+1 888-378-6240
Business address
150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR, PA
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$5,403,032
in 5 filings, $2.4M under 10b5-1 plans

Net −$5,403,032. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2023-08-11 Rodman David Malcom Chief Medical Officer Sale −80,909 $12.81 $1.0M 0
2023-08-11 Rodman David Malcom Chief Medical Officer Option exercise +76,182 $1.08 $82K 76,182
2023-08-11 Rodman David Malcom Chief Medical Officer Sale −76,182 $12.81 $976K 0
2023-08-11 Rodman David Malcom Chief Medical Officer Option exercise · Stock Option −80,909 85,293
2023-08-11 Rodman David Malcom Chief Medical Officer Option exercise · Stock Option −76,182 228,548
2023-08-11 Congleton Jon Chief Executive Officer Purchase +2,000 $12.89 $26K 1,040,318
2023-08-10 Rodman David Malcom Chief Medical Officer Option exercise +74,625 $0.54 $40K 74,625
2023-08-10 Rodman David Malcom Chief Medical Officer Sale −74,625 $13.16 $982K 0
2023-08-10 Rodman David Malcom Chief Medical Officer Option exercise · Stock Option −74,625 166,202
2023-07-12 Takahashi Takeshi Director Other disposition · Stock Option −44,000 0
2023-07-12 Slingsby Brian Taylor Director Other disposition · Stock Option −44,000 0
2023-07-12 Slingsby Brian Taylor Director Other acquisition · Stock Option +88,000 88,000
2023-04-27 Litzka Olivier Director Other disposition · Stock Option −44,000 0
2023-03-17 Rodman David Malcom Chief Medical Officer Grant or award · Stock Option +20,000 20,000
2023-03-17 Congleton Jon Chief Executive Officer Grant or award · Stock Option +99,800 99,800
2023-03-17 Levy Adam Scott CFO and Secretary Grant or award · Stock Option +20,000 20,000
2023-02-14 Levy Adam Scott CFO, Chief Bus. Off. and Secy. Purchase +6,250 $16.00 $100K 350,811
2023-02-14 AKKARAJU SRINIVAS Director Conversion +3,581,861 3,581,861
2023-02-14 AKKARAJU SRINIVAS Director Purchase +937,500 $16.00 $15.0M 4,519,361
2023-02-14 AKKARAJU SRINIVAS Director Conversion · Series A Preferred Stock −2,135,504 0

Page 21 of 23 · 446 trades